Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:GLMD
- CUSIP: N/A
- Web: www.galmedpharma.com
Capitalization:- Market Cap: $61.6 million
- Outstanding Shares: 12,149,000
Average Prices:- 50 Day Moving Avg: $4.98
- 200 Day Moving Avg: $4.34
- 52 Week Range: $2.78 - $5.79
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.76
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $467,000.00
- Price / Sales: 131.90
- Book Value: $0.91 per share
- Price / Book: 5.57
Profitability:- EBIDTA: ($16,710,000.00)
- Return on Equity: -88.41%
- Return on Assets: -74.07%
Debt:- Current Ratio: 6.53%
- Quick Ratio: 6.53%
Misc:- Average Volume: 38,308 shs.
- Beta: 2.35
- Short Ratio: 3.3
Frequently Asked Questions for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
What is Galmed Pharmaceuticals Ltd's stock symbol?
Galmed Pharmaceuticals Ltd trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals Ltd's earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced its earnings results on Monday, May, 15th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.13. The company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.29 million. View Galmed Pharmaceuticals Ltd's Earnings History.
Where is Galmed Pharmaceuticals Ltd's stock going? Where will Galmed Pharmaceuticals Ltd's stock price be in 2017?
4 analysts have issued twelve-month price targets for Galmed Pharmaceuticals Ltd's stock. Their predictions range from $6.00 to $20.00. On average, they expect Galmed Pharmaceuticals Ltd's stock price to reach $11.75 in the next twelve months. View Analyst Ratings for Galmed Pharmaceuticals Ltd.
What are analysts saying about Galmed Pharmaceuticals Ltd stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals Ltd stock:
- 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (3/29/2017)
- 2. Maxim Group analysts commented, "Galmed reported a net loss of $4.8 million, or $0.43 per share, for the three months ending on December 31, 2016 (4Q16). Research and development expenses were $4.1 million. The increase primarily resulted from research and development (clinical trial expenses) associated with the completion of enrollment in the ARREST Study. General and administrative expenses were $0.8 million. Cash and cash equivalents and marketable securities totaled $15.5 million at quarters end. Galmed highlighted the use of the ATM facility raising ~ $4.5 million." (3/24/2017)
Are investors shorting Galmed Pharmaceuticals Ltd?
Galmed Pharmaceuticals Ltd saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 93,992 shares, a decrease of 2.2% from the April 13th total of 96,138 shares. Based on an average daily trading volume, of 29,358 shares, the short-interest ratio is currently 3.2 days.
Who are some of Galmed Pharmaceuticals Ltd's key competitors?
Some companies that are related to Galmed Pharmaceuticals Ltd include VIVUS (VVUS), ProQR Therapeutics NV (PRQR), CTI BioPharma Corp (CTIC), Adverum Biotechnologies (ADVM), Arrowhead Pharmaceuticals (ARWR), Cidara Therapeutics (CDTX), CytRx (CYTR), Oramed Pharmaceuticals (ORMP), Endocyte (ECYT), Zafgen (ZFGN), Affimed NV (AFMD), Pfenex (PFNX), Applied Genetic Technologies Corp (AGTC), Vericel Corp (VCEL), Cellular Biomedicine Group (CBMG), Verastem (VSTM), ArQule (ARQL) and Infinity Pharmaceuticals (INFI).
Who owns Galmed Pharmaceuticals Ltd stock?
Who bought Galmed Pharmaceuticals Ltd stock? Who is buying Galmed Pharmaceuticals Ltd stock?
How do I buy Galmed Pharmaceuticals Ltd stock?
Shares of Galmed Pharmaceuticals Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Galmed Pharmaceuticals Ltd stock cost?
One share of Galmed Pharmaceuticals Ltd stock can currently be purchased for approximately $5.07.
Earnings History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)Earnings History by Quarter for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/15/2017 | 3/31/2017 | ($0.39) | ($0.26) | $0.29 million | $0.27 million | View | N/A |  |
| 3/23/2017 | 12/31/2016 | ($0.30) | ($0.40) | $0.22 million | $0.27 million | View | N/A | |
| 11/7/2016 | Q3 | ($0.39) | ($0.34) | | $0.19 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.35) | ($0.39) | | | View | N/A | |
| 5/16/2016 | Q116 | ($0.33) | ($0.36) | | | View | Listen | |
| 3/22/2016 | Q415 | ($0.28) | ($0.29) | | | View | Listen | |
| 11/9/2015 | Q315 | ($0.29) | ($0.23) | | | View | N/A | |
| 8/13/2015 | Q215 | ($0.28) | ($0.21) | | | View | Listen | |
| 5/13/2015 | Q1 | ($0.26) | ($0.22) | | | View | Listen | |
| 3/31/2015 | | ($0.36) | ($0.15) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)2017 EPS Consensus Estimate: ($1.32)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.43) | ($0.25) | ($0.34) |
| Q2 2017 | 3 | ($0.44) | ($0.24) | ($0.36) |
| Q3 2017 | 2 | ($0.39) | ($0.23) | ($0.31) |
| Q4 2017 | 2 | ($0.40) | ($0.22) | ($0.31) |
(Data provided by Zacks Investment Research)
Dividend History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
Latest Headlines for Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)
| Source: |
|
| Date | Headline |
|---|
 | Galmed Pharmaceuticals Ltd (GLMD) Expected to Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - May 25 at 7:54 AM |
| SunTrust Banks Brokers Decrease Earnings Estimates for Galmed Pharmaceuticals Ltd (GLMD)
www.americanbankingnews.com - May 17 at 7:56 AM |
| Galmed Pharmaceuticals Ltd (GLMD) Posts Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 16 at 5:10 PM |
| Maxim Group Analysts Give Galmed Pharmaceuticals Ltd (GLMD) a $9.00 Price Target
www.americanbankingnews.com - May 15 at 3:14 PM |
 | Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 15 at 11:19 AM |
| Galmed Pharmaceuticals reports 1Q loss
finance.yahoo.com - May 15 at 11:19 AM |
| Galmed Pharmaceuticals Ltd (GLMD) Sees Large Decrease in Short Interest
www.americanbankingnews.com - May 14 at 9:14 AM |
| Galmed Pharmaceuticals First Quarter 2017 Conference Call and Webcast Scheduled for Monday, May 15th, 2017
finance.yahoo.com - May 8 at 5:14 PM |
 | Therapix Biosciences (TRPX) Announces the Appointment of Josh Blacher as CFO
www.streetinsider.com - May 4 at 12:08 PM |
 | Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
www.prnewswire.com - May 3 at 5:14 PM |
| Brokerages Expect Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $260,000.00
www.americanbankingnews.com - May 3 at 12:25 PM |
| Galmed Pharmaceuticals (GLMD) Given Daily News Sentiment Score of 0.12
www.americanbankingnews.com - May 2 at 6:36 PM |
| Analysts Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 2 at 12:06 AM |
| Galmed Pharmaceuticals (GLMD) Given Media Impact Score of -0.12
www.americanbankingnews.com - April 28 at 12:40 PM |
| Galmed Pharmaceuticals (GLMD) Getting Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 10:46 AM |
| Galmed Pharmaceuticals (GLMD) Receives News Sentiment Score of 0.19
www.americanbankingnews.com - April 20 at 7:00 PM |
| Galmed Pharmaceuticals (GLMD) Getting Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 17 at 1:23 PM |
| Galmed Pharmaceuticals (GLMD) Earning Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 14 at 12:06 PM |
| Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Earnings of -$0.36 Per Share
www.americanbankingnews.com - April 10 at 8:28 PM |
| Galmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol™ has a Potential Direct Effect on Liver Fibrosis
finance.yahoo.com - April 7 at 10:03 AM |
| Galmed Pharmaceuticals Ltd (GLMD) PT Set at $9.00 by Maxim Group
www.americanbankingnews.com - April 5 at 6:45 PM |
| Research Analysts Offer Predictions for Galmed Pharmaceuticals Ltd's Q1 2017 Earnings (GLMD)
www.americanbankingnews.com - March 31 at 12:15 PM |
| Galmed Pharmaceuticals Ltd (GLMD) to Post Q3 2017 Earnings of ($0.39) Per Share, FBR & Co Forecasts
www.americanbankingnews.com - March 30 at 9:52 AM |
| Galmed Pharmaceuticals' (GLMD) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - March 30 at 9:07 AM |
| Galmed Pharmaceuticals Ltd (GLMD) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 8:25 PM |
| Maxim Group Reaffirms Buy Rating for Galmed Pharmaceuticals Ltd (GLMD)
www.americanbankingnews.com - March 29 at 12:07 PM |
| Galmed Pharmaceuticals Ltd (GLMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:55 PM |
| Galmed Pharmaceuticals Ltd (GLMD) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - March 28 at 7:28 PM |
| GALMED PHARMACEUTICALS LTD. Financials
finance.yahoo.com - March 28 at 5:04 PM |
| SunTrust Banks Weighs in on Galmed Pharmaceuticals Ltd's FY2021 Earnings (GLMD)
www.americanbankingnews.com - March 27 at 10:46 AM |
| Galmed Pharmaceuticals Ltd (GLMD) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - March 24 at 11:13 AM |
| Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
finance.yahoo.com - March 23 at 9:01 AM |
| 7:45 am Galmed Pharma reports Q4 results; announces new data from recently completed pre-clinical studies demonstrating Aramchol's potential direct effect on liver fibrosis to be presented at the International Liver Congress
finance.yahoo.com - March 23 at 9:01 AM |
| Galmed Pharmaceuticals Ltd (GLMD) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 17 at 9:06 PM |
| Galmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017
finance.yahoo.com - March 16 at 6:39 PM |
 | EGLT Gets Long Awaited FDA Approval, PTCT Breathes Easy, GLMD On Track - Nasdaq
www.nasdaq.com - January 11 at 11:03 PM |
| Galmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
finance.yahoo.com - January 9 at 4:14 PM |
Galmed Pharmaceuticals Ltd (GLMD) Chart for Sunday, May, 28, 2017
